Celularity

Celularity

Founded in 2017 by Robert Hariri, Celularity emerged from Hariri's earlier work at Celgene Cellular Therapeutics and Anthrogenesis, where he pioneered the harvesting of stem and progenitor cells from human placental tissue. Hariri, also co-founder of Human Longevity Inc., structured Celularity around a proprietary biobank and manufacturing platform that converts donated postpartum placentas into cryopreserved cellular therapies. The underlying thesis is that placental-derived cells possess unique immunomodulatory and regenerative properties, making them viable for allogeneic use without the rejection risks that complicate autologous or bone-marrow-derived cell therapies. Celularity's pipeline spans oncology, degenerative disease, and infectious disease, with a focus on unmodified natural killer (NK) cells, engineered NK cells, and mesenchymal-like stromal cells. Its lead oncology asset, CYNK-001, is an allogeneic NK cell therapy that has entered clinical trials for glioblastoma multiforme, acute myeloid leukemia, and COVID-19 complications, with trial sites across the U.S. and Asia. The company also markets a placental-derived biomaterial product line for wound care and surgical recovery. Celularity pursues a vertically integrated model: it controls placenta collection from donor hospitals, bioprocessing in its Florham Park, NJ facility, and clinical development through Phase II trials — a structure that echoes the early Celgene playbook Hariri knew well. Celularity went public via a SPAC merger in July 2021, led by GX Acquisition Corp., with a pro forma enterprise value of approximately $1.7 billion at closing (per SEC filings). Shortly after, in January 2022, the company expanded its placental-biomaterial commercial footprint through a licensing agreement with a European distributor. As of mid-2024, Celularity has faced post-SPAC headwinds common to development-stage biotechs — including Nasdaq listing compliance challenges and capital-raise dilutions — but continues to report clinical enrollment in multiple Phase I/II solid-tumor and hematologic malignancy trials. The company operates with a lean leadership team anchored by Hariri, and maintains its manufacturing and R&D hub in New Jersey. Celularity's structural distinction is its biologic feedstock model: rather than relying on single donors, the company treats placental tissue as a scalable, replenishable raw material. This positions it between a traditional biopharma and a manufacturing-scale biologics platform. Its public-company structure also exposes it to the capital-market cycles of a pre-revenue biotech, creating a governance dynamic where clinical milestones and stock liquidity directly shape strategic runway.